SELLAS Life Sciences Group (RXK3) Price & Analysis

1 Followers

RXK3 Stock Chart & Stats

€9.02

-€0.18(-1.96%)

At close: Jul 30 4:00 PM EDT

€9.02

-€0.18(-1.96%)

Day’s Range― - ―

52-Week Range€1.20 - €14.95

Previous CloseN/A

Volume500.00

Average Volume (3M)1.35K

Market Cap

€2.27B

Enterprise Value€2.65K

Total Cash (Recent Filing)€138.44M

Total Debt (Recent Filing)€737.00K

Price to Earnings (P/E)―

Beta0.66

Next Earnings

Nov 18, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding201,945,710

10 Day Avg. Volume1,380

30 Day Avg. Volume1,352

Financial Highlights & Ratios

PEG Ratio0.30

Price to Book (P/B)5.80

Price to Sales (P/S)0.00

P/FCF Ratio-14.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€23.74

Price Target Upside163.19% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.18

Revenue Forecast (FY)€31.66M

Bulls Say, Bears Say

Bulls Say

Very Low LeverageMinimal debt reduces solvency and interest-burden risk, giving SELLAS greater flexibility to fund clinical development. The repaired equity base also provides a stronger financial platform than the negative-equity position reported in 2023.

Improved LiquidityThe larger cash balance and additional warrant proceeds extend funding capacity for operations and clinical programs. This can reduce near-term financing pressure, although the capital was obtained through additional equity issuance.

Partnered GPS Commercialization PotentialAn exclusive regional partner provides external development and commercialization resources for GPS while preserving potential milestone economics. If the program advances, this structure could create non-dilutive value beyond SELLAS’s internal funding capacity.

Bears Say

No Current Commercial RevenueSELLAS lacks recurring commercial revenue and remains dependent on clinical development success to establish operating scale. Persistent losses indicate that the business model has not yet demonstrated sustainable earnings or a self-funding revenue base.

Persistent Cash Burn And Dilution RiskNegative cash generation means SELLAS must continue relying on external capital to fund operations. Equity-linked financing can extend the runway, but recurring issuance transfers value from existing holders and leaves funding risk tied to market access.

Adverse Arbitration OutcomeThe binding ruling removes a potential near-term contractual recovery and imposes an additional cash cost. It also leaves the Greater China GPS relationship dependent on the existing license terms rather than a more favorable resolution for SELLAS.

SELLAS Life Sciences Group News

Moderna data bode well for Sellas into imminent readout, says Maxim

Maxim views Moderna’s (MRNA) melanoma mRNA cancer vaccine results this morning as a “win for cancer vaccines.” Sellas...

10h ago

SLS

MRNA

Sellas Life Sciences price target raised to $35 from $25 at Alliance Global

Alliance Global analyst James Molloy raised the firm’s price target on Sellas Life Sciences (SLS) to $35 from...

3d ago

SLS

Sellas Life Sciences options imply 8.0% move in share price post-earnings

Pre-earnings options volume in Sellas Life Sciences (SLS) is normal with calls leading puts 2:1. Implied volatility suggests...

8d ago

SLS

Moderately bullish activity in Sellas Life Sciences with shares up 7.39%

Moderately bullish activity in Sellas Life Sciences (SLS), with shares up 74c, or 7.39%, near $10.75. Options volume...

16d ago

SLS

Cboe data shows mixed options sentiment in Sellas Life Sciences with shares down 3.3%

Cboe data shows mixed options sentiment in Sellas Life Sciences (SLS), with shares down 34c near $9.95. Options...

19d ago

SLS

Moderately bullish activity in Sellas Life Sciences with shares down 11.17%

Moderately bullish activity in Sellas Life Sciences (SLS), with shares down $1.21 near $9.62. Options volume running well...

22d ago

SLS

Unusually active option classes on open July 27th

Unusual total active option classes on open include: Leverage Shares 2X Long NBIS Daily ETF (NBIG), Nutrien (NTR),...

23d ago

SELLAS Life Sciences Faces Adverse Arbitration Ruling

SELLAS Life Sciences Group ( ($SLS) ) has issued an update. On July 24, 2026, a sole arbitrator...

23d ago

SLS

Sellas Life Sciences rises 11.0%

Sellas Life Sciences (SLS) is up 11.0%, or $1.29 to $13.04. Published first on TheFly – the ultimate...

1M ago

SLS

Sellas Life Sciences rises 10.2%

Sellas Life Sciences (SLS) is up 10.2%, or $1.20 to $12.95. Published first on TheFly – the ultimate...

1M ago

SLS

Sellas Life Sciences price target raised to $25 from $10 at Alliance Global

Alliance Global analyst James Molloy raised the firm’s price target on Sellas Life Sciences (SLS) to $25 from...

1M ago

SLS

SELLAS Updates Executive Severance and Change-of-Control Terms

The latest announcement is out from SELLAS Life Sciences Group ( ($SLS) ). On June 24, 2026, SELLAS...

2M ago

SLS

SELLAS Stockholders Approve Governance and Equity Plan Changes

The latest update is out from SELLAS Life Sciences Group ( ($SLS) ). On June 16, 2026, SELLAS...

2M ago

SLS

SELLAS Life Sciences boosts liquidity through warrant exercises

The latest announcement is out from SELLAS Life Sciences Group ( ($SLS) ). SELLAS Life Sciences Group, Inc....

3M ago

SLS

RXK3 FAQ

What was SELLAS Life Sciences Group’s price range in the past 12 months?

SELLAS Life Sciences Group lowest stock price was €1.20 and its highest was €14.95 in the past 12 months.

What is SELLAS Life Sciences Group’s market cap?

SELLAS Life Sciences Group’s market cap is €2.27B.

When is SELLAS Life Sciences Group’s upcoming earnings report date?

SELLAS Life Sciences Group’s upcoming earnings report date is Nov 18, 2026 which is in 90 days.

How were SELLAS Life Sciences Group’s earnings last quarter?

SELLAS Life Sciences Group released its earnings results on Aug 11, 2026. The company reported -€0.043 earnings per share for the quarter, missing the consensus estimate of -€0.039 by -€0.004.

Is SELLAS Life Sciences Group overvalued?

According to Wall Street analysts SELLAS Life Sciences Group’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SELLAS Life Sciences Group pay dividends?

SELLAS Life Sciences Group does not currently pay dividends.

What is SELLAS Life Sciences Group’s EPS estimate?

SELLAS Life Sciences Group’s EPS estimate is -0.04.

How many shares outstanding does SELLAS Life Sciences Group have?

SELLAS Life Sciences Group has 201,945,710 shares outstanding.

What happened to SELLAS Life Sciences Group’s price movement after its last earnings report?

SELLAS Life Sciences Group reported an EPS of -€0.043 in its last earnings report, missing expectations of -€0.039. Following the earnings report the stock price went up 7.438%.

Which hedge fund is a major shareholder of SELLAS Life Sciences Group?

Currently, no hedge funds are holding shares in DE:RXK3

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

SELLAS Life Sciences Group Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

350.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group (RXK3) Earnings & Revenues

Historic Earnings Reports

RXK3 Stock 12 Month Forecast

Average Price Target

€23.74

▲(163.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","13":"€13","26":"€26","6.5":"€6.5","19.5":"€19.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25.898103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€25.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.73992775,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€23.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.5817525,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.5,13,19.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.68,10.004469461538461,11.328938923076922,12.653408384615386,13.977877846153845,15.302347307692308,16.62681676923077,17.95128623076923,19.27575569230769,20.600225153846154,21.924694615384617,23.249164076923076,24.57363353846154,{"y":25.898103,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.68,9.838455980769231,10.996911961538462,12.155367942307691,13.313823923076923,14.472279903846154,15.630735884615383,16.789191865384616,17.947647846153846,19.106103826923075,20.264559807692308,21.423015788461537,22.581471769230767,{"y":23.73992775,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.68,9.672442499999999,10.664885,11.6573275,12.64977,13.6422125,14.634654999999999,15.6270975,16.61954,17.6119825,18.604425,19.596867500000002,20.589309999999998,{"y":21.5817525,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.612,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.328,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.652,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.348,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.115,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.695,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.02,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.779,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.75,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >